Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
March 2, 2018 – XYMOGEN, Inc., a leading manufacturer of medical foods and dietary supplements, announced today that is has prevailed in a lawsuit with Thorne Research. On February 20, 2018, after a six-day trial, a jury in the United States District Court for the District of Utah ruled for XYMOGEN. The jury found that XYMOGEN’s proprietary and highly-absorbed CoQMax product was actually invented by a chemist from XYMOGEN’s manufacturer thereby invalidating Thorne’s patent on their product.
|
|||
“I am extremely pleased that the jury saw fit to discredit Thorne’s claims and invalidate their patent”, said Brian Blackburn, XYMOGEN’s Founder and CEO. “Claiming a patent on an invention by a third-party misleads the public, and I hope the jury’s verdict will deter others from similar practices.”
About XYMOGEN:
To learn more about XYMOGEN, a family-owned, health sciences company, and its formulas, distribution, and community involvement, visit XYMOGEN.com, email [email protected], or call 800-647-6100. XYMOPrint, a full-service digital printer and design studio, XYMOGEN LOGISTICS, a third-party fulfillment, warehousing, and shipping provider; and PharmaceutiX Medical Foods are all subsidiaries of XYMOGEN.
6900 Kingesporte Parkway
Orlando, Fl
Tel: 800-647-6100
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a48371c-6283-4c53-afa1-bb7a889b35d1
Meghan Blackburn XYMOGEN 800-647-6100, Ext. 8875 [email protected]
